XKRX:314130 (Korea (the Republic of))
Â
Ordinary Shares
â‚©
2,350
+145 (+6.58%)
Apr 1
What is a stock summary page? Click here for an overview.
Business Description
Genome & Co
ISIN : KR7314130006
Share Class Description:
XKRX:314130: Ordinary SharesCompare
Compare
Traded in other countries / regions
314130.Korea Index Membership
KOSDAQ Composite Index IPO Date
2018-12-26Description
Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.53 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 0.66 | |||||
| Debt-to-EBITDA | -1.86 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.85 | |||||
| Beneish M-Score | -2.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 278.5 | |||||
| 3-Year EBITDA Growth Rate | 23.1 | |||||
| 3-Year EPS without NRI Growth Rate | 25.5 | |||||
| 3-Year FCF Growth Rate | 15.1 | |||||
| 3-Year Book Growth Rate | -22.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.78 | |||||
| 9-Day RSI | 44.54 | |||||
| 14-Day RSI | 42.35 | |||||
| 3-1 Month Momentum % | -2 | |||||
| 6-1 Month Momentum % | -25.35 | |||||
| 12-1 Month Momentum % | -42.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.08 | |||||
| Quick Ratio | 2.89 | |||||
| Cash Ratio | 2.71 | |||||
| Days Inventory | 146.7 | |||||
| Days Sales Outstanding | 19.91 | |||||
| Days Payable | 18.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.3 | |||||
| Shareholder Yield % | -18.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.48 | |||||
| Operating Margin % | -87.22 | |||||
| Net Margin % | -72.49 | |||||
| FCF Margin % | -73.95 | |||||
| ROE % | -36.15 | |||||
| ROA % | -12.94 | |||||
| ROIC % | -25.89 | |||||
| 3-Year ROIIC % | 59.93 | |||||
| ROC (Joel Greenblatt) % | -72.41 | |||||
| ROCE % | -19.39 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.47 | |||||
| PB Ratio | 1.53 | |||||
| Price-to-Tangible-Book | 2.91 | |||||
| EV-to-EBIT | -3.06 | |||||
| EV-to-EBITDA | -4.38 | |||||
| EV-to-Revenue | 2.73 | |||||
| EV-to-FCF | -3.67 | |||||
| Price-to-GF-Value | 0.16 | |||||
| Earnings Yield (Greenblatt) % | -32.73 | |||||
| FCF Yield % | -28.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genome & Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 27,744.682 | ||
| EPS (TTM) (â‚©) | -798.041 | ||
| Beta | 1.04 | ||
| 3-Year Sharpe Ratio | -0.84 | ||
| 3-Year Sortino Ratio | -1.04 | ||
| Volatility % | 54.83 | ||
| 14-Day RSI | 42.35 | ||
| 14-Day ATR (â‚©) | 128.711365 | ||
| 20-Day SMA (â‚©) | 2424 | ||
| 12-1 Month Momentum % | -42.04 | ||
| 52-Week Range (â‚©) | 2170 - 7335 | ||
| Shares Outstanding (Mil) | 30.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genome & Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genome & Co Stock Events
| Event | Date | Price (â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genome & Co Frequently Asked Questions
What is Genome & Co(XKRX:314130)'s stock price today?
The current price of XKRX:314130 is â‚©2350.00. The 52 week high of XKRX:314130 is â‚©7335.00 and 52 week low is â‚©2170.00.
When is next earnings date of Genome & Co(XKRX:314130)?
The next earnings date of Genome & Co(XKRX:314130) is .
Does Genome & Co(XKRX:314130) pay dividends? If so, how much?
Genome & Co(XKRX:314130) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers